Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 27, 2025
SS Innovations International, Inc. Achieves Another Milestone by Successfully Performing Over 2,000 km North-to-South Robotic Cardiac Telesurgery with its SSi Mantra 3 Surgical Robotic System
GlobeNewswire
·
March 27, 2025
The SSI Mantra 3 Surgical Robotic System enabled a seamless connection from SS Innovations headquarters in Gurugram, India to Aster CMI Hospital in Bengaluru, India covering a distance over 2,000 km. The SSi Mantra, India’s first CDSCO*-approved surgical …
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
GlobeNewswire
·
March 27, 2025
Reinforces potential of nebokitug to become the first approved drug with disease-modifying activity for PSC--a deadly disorder that currently has no effective treatments Treatment in PSC patients with moderate/advanced disease for 48 weeks resulted in …
LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
GlobeNewswire
·
March 27, 2025
-Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with the NIH on LB-100's Potential in Enhancing Cancer …
ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025
GlobeNewswire
·
March 27, 2025
GARDEN CITY, NY, March 27, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that they will be presenting full year 2024 financial …
Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting
GlobeNewswire
·
March 27, 2025
Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path forward Raanana, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative …
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 27, 2025
Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives process underway to maximize value creation across all assets in the company Strong financial position with …
Organovo Provides Business Update
GlobeNewswire
·
March 27, 2025
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today provided a …
Wellgistics Health Annual Letter to Shareholders From the Office of the CEO March 2025
GlobeNewswire
·
March 27, 2025
Dear Shareholders, TAMPA, FL, March 27, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX) (“Wellgistics Health”), This time last year, Wellgistics was a private company, weathering the pressures of a broken pharmaceutical supply chain …
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 27, 2025
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the course of the next 18 months provide significant value- …
SpyGlass Pharma Appoints Chetan Pujara, Ph.D., as Chief Research & Development Officer
GlobeNewswire
·
March 27, 2025
Dr. Pujara brings extensive industry experience to guide late-stage development of the SpyGlass Drug Delivery Platform ALISO VIEJO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, today …
Evaxion to announce business update and full year 2024 financial results on April 1, 2025
GlobeNewswire
·
March 27, 2025
COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial …
4DMT to Participate in Upcoming Investor Conferences
GlobeNewswire
·
March 27, 2025
EMERYVILLE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment …
匈牙利Helvetic牙科诊疗中心2024年再创佳绩，成为布达佩斯最佳牙科诊所
EIN Presswire
·
March 27, 2025
BUDAPEST, BUDAPEST, HUNGARY, March 27, 2025 /EINPresswire.com/ -- Helvetic 牙科诊疗中心被誉为匈牙利最佳牙科诊所，在2024年再次取得了卓越的成绩。2024年新增四个诊室的决定是一个及时且战略性的举措，使诊所能够迅速满足日益增长的海外牙科理疗需求，尤其是在快速发展的牙科旅游领域。 通过此次扩容，Helvetic …
BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025
GlobeNewswire
·
March 27, 2025
CARSON CITY, Nev., March 27, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced …
Galatea Bio Secures $25M to Develop Global Biobank and Enable Precision Health at Scale for All
GlobeNewswire
·
March 27, 2025
Building the world’s largest biobank with data from global populations to accelerate biomarker and drug discovery and development of next-generation diagnostics. Secured $25M in funding from F-Prime, Helios Digital Ventures, Digitalis Ventures, CEI …
New Data to Be Presented at Upcoming Congresses Showcase Cerevance's Advanced Clinical Program in Parkinson’s Disease and Deep Pipeline for CNS-based Disorders
GlobeNewswire
·
March 27, 2025
Topline results from Phase 2 ASCEND trial of solengepras as a monotherapy treatment for early-stage Parkinson’s to be presented First presentation of data from Phase 1 trial of novel KCNK13 inhibitor for CNS diseases targeting neuroinflammation Additional …
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting
GlobeNewswire
·
March 27, 2025
STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American …
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
March 27, 2025
SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on March 24, 2025, the independent members of the Board of Directors granted inducement equity awards to (i) seven …
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 27, 2025
Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025 Well- …
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference
GlobeNewswire
·
March 27, 2025
- Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in six-minute walk distance, cardiac effort and quality of life - Case study highlights the long-term safety and tolerability of …